<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343548</url>
  </required_header>
  <id_info>
    <org_study_id>1019-211194</org_study_id>
    <nct_id>NCT03343548</nct_id>
  </id_info>
  <brief_title>Epidural Magnesium Sulfate for Post-thoracotomy Pain Control</brief_title>
  <official_title>The Effect of Adjuvant Epidural Magnesium Sulfate to Bupivacaine and Morphine on Post-thoracotomy Pain Control: A Randomized Double Blind Clinical Trial Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Institute of Tuberculosis and Lung Disease, Iran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Institute of Tuberculosis and Lung Disease, Iran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain after thoracotomy is very severe and may cause pulmonary complications. Thoracic
      epidural analgesia has greatly decreased the pain experience and its consequences. However,
      new ways of decreasing post-operative opioid drugs consumption is an important issue of
      research. We aim to evaluate the effect of adding epidural magnesium sulfate to bupivacaine
      and morphine on pain control and the amount of opioid consumption after thoracotomy. Eighty
      patients undergoing thoracotomy at a tertiary cardiothoracic referral center will be enrolled
      in a randomized double blind trial. Patients randomly will be allocated in two groups.
      Bupivacaine (12.5 mg) plus morphine (2 mg) will be administered epidurally for all patients
      at the end of operation. Patients in group I will be received epidural magnesium sulfate (50
      mg) and patients in Group II will be received normal saline as an adjuvant. Visual analog
      scale (VAS) score and the amount of morphine consumption will be measured during 24 hours
      post-operation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>severity of post-thoracotomy pain</measure>
    <time_frame>24 hours after thoracotomy</time_frame>
    <description>VAS (visual analog scale: 0-10 cm (0 cm = no pain and 10 cm = the worst pain)) score will be measured</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>magnesium group (Mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control group (C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>magnesium sulfate</intervention_name>
    <description>2cc of magnesium sulfate ( 50%) will be administered epidurally</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>2cc of normal saline will be administered epidurally</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists physical statuses I-III

          -  Undergoing thoracotomy

        Exclusion Criteria:

          -  Known hypersensitivity to magnesium sulfate

          -  Renal failure

          -  Hepatic dysfunction

          -  Severe obesity

          -  Psychotic or neurologic diseases

          -  Currently taking opioid or calcium channel blocker

          -  AV block degree II or III

          -  Refused to participate in trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shadi Baniasadi</name>
      <address>
        <city>Tehran</city>
        <zip>19569-44413</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2017</study_first_submitted>
  <study_first_submitted_qc>November 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Institute of Tuberculosis and Lung Disease, Iran</investigator_affiliation>
    <investigator_full_name>Shadi Baniasadi</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

